Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Exp Eye Res ; 206: 108546, 2021 05.
Article in English | MEDLINE | ID: mdl-33773977

ABSTRACT

Transforming growth factor beta (TGFß) and bone morphogenetic protein (BMP) signaling play opposing roles in epithelial-mesenchymal transition (EMT) of lens epithelial cells, a cellular process integral to the pathogenesis of fibrotic cataract. We previously showed that BMP-7-induced Smad1/5 signaling blocks TGFß-induced Smad2/3-signaling and EMT in rat lens epithelial cell explants. To further explore the antagonistic role of BMPs on TGFß-signaling, we tested the capability of BMP-4 or newly described BMP agonists, ventromorphins, in blocking TGFß-induced lens EMT. Primary rat lens epithelial explants were treated with exogenous TGFß2 alone, or in combination with BMP-4 or ventromorphins. Treatment with TGFß2 induced lens epithelial cells to undergo EMT and transdifferentiate into myofibroblastic cells with upregulated α-SMA and nuclear translocation of Smad2/3 immunofluorescence. BMP-4 was able to suppress this EMT without blocking TGFß2-nuclear translocation of Smad2/3. In contrast, the BMP agonists, ventromorphins, were unable to block TGFß2-induced EMT, despite a transient and early ability to significantly reduce TGFß2-induced nuclear translocation of Smad2/3. This intriguing disparity highlights new complexities in the responsiveness of the lens to differing BMP-related signaling. Further research is required to better understand the antagonistic relationship between TGFß and BMPs in lens EMT leading to cataract.


Subject(s)
Bone Morphogenetic Protein 4/agonists , Cataract/drug therapy , Lens, Crystalline/drug effects , Animals , Bone Morphogenetic Protein 4/metabolism , Cataract/metabolism , Cataract/pathology , Disease Models, Animal , Epithelial-Mesenchymal Transition/drug effects , Female , Lens, Crystalline/metabolism , Lens, Crystalline/pathology , Male , Rats , Rats, Wistar , Signal Transduction , Transforming Growth Factor beta/metabolism
2.
Steroids ; 74(13-14): 1066-72, 2009.
Article in English | MEDLINE | ID: mdl-19723531

ABSTRACT

We recently identified that cholesterol myristate in traditional Chinese medicine (TCM) is the active compound that increases proliferation of mesenchymal stem cell (MSCs). The present study is further to determine what signal pathway involves in effect of cholesterol myristate. Reverse transcription-PCR, Western blot and ELISA analysis show that cholesterol myristate increases the release of bone morphogenetic protein 4 (BMP4) from MSCs and the expression in the intracellular levels of BMP4 in a time- and dose dependent manner. However, structurally related steroids such as cholesterol and cholesten presented in TCM, both lack of the myristate, did not affect the secretion and expression of BMP4 on MSCs. These finds suggest that myristate is essential for the effects of cholesterol myristate. Furthermore, cholesterol myristate significantly increase BMPRIB levels of MSCs and the number of BMPRIB positive cells in a time- and dose dependent manner, but not BMPR IA or BMPR II. Our results indicate that action of cholesterol myristate may activate the BMP4-BMPRIB autocrine. Moreover, a blocking antibody against BMP4 or the BMP4 antagonist, noggin, partially reduced the effects of cholesterol myristate on MSCs proliferation. Thus, this study is to provide evidence that autocrine BMP4 signaling involves effect of cholesterol myristate on MSCs proliferation.


Subject(s)
Autocrine Communication/drug effects , Bone Morphogenetic Protein 4/metabolism , Bone Morphogenetic Protein Receptors, Type I/metabolism , Cell Proliferation/drug effects , Cholesterol Esters/pharmacology , Mesenchymal Stem Cells/drug effects , Animals , Antibodies, Neutralizing/immunology , Autocrine Communication/physiology , Bone Morphogenetic Protein 4/agonists , Bone Morphogenetic Protein 4/antagonists & inhibitors , Bone Morphogenetic Protein Receptors, Type I/agonists , Carrier Proteins/pharmacology , Mesenchymal Stem Cells/metabolism , Mesenchymal Stem Cells/physiology , Rats , Rats, Sprague-Dawley , Signal Transduction/drug effects
SELECTION OF CITATIONS
SEARCH DETAIL